<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02687906</url>
  </required_header>
  <id_info>
    <org_study_id>Rempex 507</org_study_id>
    <nct_id>NCT02687906</nct_id>
  </id_info>
  <brief_title>Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections</brief_title>
  <acronym>TANGOKIDS</acronym>
  <official_title>An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Melinta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding,&#xD;
      pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18&#xD;
      years of age with serious bacterial infections&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the current era of increased resistance to extended spectrum cephalosporins, carbapenem&#xD;
      antimicrobial agents are frequently the antibiotics of &quot;last defense&quot; for the most resistant&#xD;
      pathogens in serious infections, including those found in complicated Urinary Tract&#xD;
      Infections (cUTI). The recent dissemination of serine carbapenemases (e.g. KPC) in&#xD;
      Enterobacteriaceae in many hospitals worldwide now poses a considerable threat to the&#xD;
      carbapenems and other members of the beta-lactam class of antimicrobial agents.&#xD;
&#xD;
      Rempex developed meropenem-vaborbactam administered as a fixed combination by IV infusion, to&#xD;
      treat serious Gram-negative infections, such as cUTIs, including those infections caused by&#xD;
      bacteria resistant to currently available carbapenems.&#xD;
&#xD;
      This study is an open label, dose-finding, pharmacokinetics, safety, and tolerability study&#xD;
      of a single dose infusion of meropenem-vaborbactam in pediatric subjects from birth to less&#xD;
      than 18 years of age with serious bacterial infections&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: AUC0-∞</measure>
    <time_frame>From pre-dose until 6 hours after the start of the infusion</time_frame>
    <description>AUC from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Cmax</measure>
    <time_frame>From pre-dose until 6 hours after the start of the infusion</time_frame>
    <description>maximum measured plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: time to maximum plasma concentration (Tmax)</measure>
    <time_frame>From pre-dose until 6 hours after the start of the infusion</time_frame>
    <description>time to Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: drug clearance (CL)</measure>
    <time_frame>From pre-dose until 6 hours after the start of the infusion</time_frame>
    <description>total body clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: t1/2</measure>
    <time_frame>From pre-dose until 6 hours after the start of the infusion</time_frame>
    <description>elimination half- life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Cmin</measure>
    <time_frame>From pre-dose until 6 hours after the start of the infusion</time_frame>
    <description>minimum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Vss</measure>
    <time_frame>From pre-dose until 6 hours after the start of the infusion</time_frame>
    <description>Volume of distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability: AEs/SAEs</measure>
    <time_frame>From assent / consent until day 7 safety follow up call</time_frame>
    <description>a composite measure of the number and types of AEs/SAEs encountered and relationship to time of dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability: clinical safety laboratory results</measure>
    <time_frame>From assent / consent until day 7 safety follow up call</time_frame>
    <description>A composite measure of multiple laboratory results assessing the clinical significance of any changes from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability: vital signs</measure>
    <time_frame>From assent / consent until day 7 safety follow up call</time_frame>
    <description>A composite of multiple vital sign measurements, assessing the clinical significance of any changes from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability: ECGs</measure>
    <time_frame>From assent / consent until day 7 safety follow up call</time_frame>
    <description>A composite of multiple ECG measurements, assessing the clinical significance of any changes from baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Single dose IV meropenem-vaborbactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vabomere (meropenem-vaborbactam) for IV injection will be administered as a single dose diluted in normal saline infused IV over 3 hours&#xD;
The starting dose for Cohort 1 (ages 12 to &lt;18 years) was 40 mg/kg meropenem and 40 mg/kg vaborbactam, or 2 g meropenem 2 g vaborbactam for subjects ≥50kg in weight. Following completion of Cohorts 1 and 2 an independent DSMB assessed the PK, safety and tolerability data and determined that the new starting dose for Cohort 3 (ages 2 to &lt; 6 years) would be 60 mg/kg or 2 g meropenem 2 g vaborbactam for subjects &gt;33 kg in weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vabomere</intervention_name>
    <description>Vabomere (meropenem-vaborbactam) for IV injection</description>
    <arm_group_label>Single dose IV meropenem-vaborbactam</arm_group_label>
    <other_name>Combination meropenem and vaborbactam</other_name>
    <other_name>carbapenem and beta-lactamase inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A signed and dated written informed consent from the parent or legal representative&#xD;
             and a subject assent (according to local IRB requirements);&#xD;
&#xD;
          2. Male or female from birth to &lt; 18 years of age;&#xD;
&#xD;
          3. Are hospitalized, in stable condition, and receiving systemic antibiotics for a known&#xD;
             or suspected bacterial infection; or subjects receiving peri-operative prophylactic&#xD;
             use of antibiotics;&#xD;
&#xD;
          4. The subject will be observed in the hospital for at least 6 hours after the study drug&#xD;
             is administered;&#xD;
&#xD;
          5. If female and has reached menarche, or has reached Tanner Stage 3 breast development&#xD;
             (even if not having reached menarche), the subject is practicing appropriate birth&#xD;
             control or is sexually abstinent;&#xD;
&#xD;
          6. Sufficient intravascular access (peripheral or central) to receive study drug.&#xD;
&#xD;
        Subjects will be excluded from the study if any of the following exclusion criteria apply&#xD;
        prior to randomization:&#xD;
&#xD;
          1. Signs of severe sepsis including:&#xD;
&#xD;
               1. Shock or profound hypotension that is not responsive to fluid challenge;&#xD;
&#xD;
               2. Hypothermia (core temperature &lt; 35.6 ºC or 96.1 ºF);&#xD;
&#xD;
               3. Disseminated intravascular coagulation as evidenced by prothrombin time or&#xD;
                  partial thromboplastin time ≥ 2X the ULN or platelets &lt; 50% of the lower limit of&#xD;
                  normal;&#xD;
&#xD;
          2. Any surgical or medical condition which, in the opinion of the investigator, would put&#xD;
             the subject at increased risk or is likely to interfere with study procedures or PK of&#xD;
             the study drug;&#xD;
&#xD;
          3. Females who are of childbearing potential and unwilling to practice abstinence or use&#xD;
             at least two methods of contraception (oral contraceptives, barrier methods, approved&#xD;
             contraceptive implant) during the entire study period;&#xD;
&#xD;
          4. Female adolescent subjects who are pregnant or breastfeeding or have a positive serum&#xD;
             β-hCG pregnancy test at screening and at pre-dose Day 1;&#xD;
&#xD;
          5. Males who are unwilling to practice abstinence or use an acceptable method of broth&#xD;
             control during the entire study period (i.e. condom with spermicide);&#xD;
&#xD;
          6. Renal function at screening as estimated by creatinine clearance &lt; 50 mL/min using the&#xD;
             Cockcroft-Gault formula;&#xD;
&#xD;
          7. Treatment within 30 days prior to enrollment with valproic acid;&#xD;
&#xD;
          8. Treatment within 30 days prior to enrollment with probenecid;&#xD;
&#xD;
          9. Evidence of significant hepatic disease or dysfunction, including known acute viral&#xD;
             hepatitis or hepatic encephalopathy;&#xD;
&#xD;
         10. Neutropenia with absolute neutrophil count (ANC) &lt; 500 cells/mm3;&#xD;
&#xD;
         11. Aspartate aminotransferase or alanine aminotransferase ≥ 3X ULN or total bilirubin ≥&#xD;
             1.5X ULN;&#xD;
&#xD;
         12. Receipt of any investigational medication or investigational device within 30 days&#xD;
             prior to enrollment;&#xD;
&#xD;
         13. Prior exposure to vaborbactam or Vabomere;&#xD;
&#xD;
         14. Use of meropenem within 48 hours of administration of study drug or 12 hours after&#xD;
             study drug administration;&#xD;
&#xD;
         15. Known significant hypersensitivity to any beta-lactam antibiotic;&#xD;
&#xD;
         16. Unable or unwilling in the judgment of the Investigator, to comply with the protocol;&#xD;
&#xD;
         17. An employee of the Investigator or study center with direct involvement in the&#xD;
             proposed study or other studies under the direction of that Investigator or study&#xD;
             center, as well as a family member of the employee or the Investigator;&#xD;
&#xD;
         18. BMI outside the range (below the 5th percentile or above the 95th percentile) for&#xD;
             height, age and weight except for children &lt; 2 years of age.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Melinta Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>1-844-633-6568</phone>
    <email>medinfo@melinta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Lang</last_name>
      <email>ELang@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Jaime Deville, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Farrell, RN</last_name>
      <phone>858-966-8381</phone>
      <email>mfarrell@rchsd.org</email>
    </contact>
    <contact_backup>
      <last_name>Sara Hingtgen, RN</last_name>
      <phone>858-966-8381</phone>
      <email>shingtgen@rchsd.org</email>
    </contact_backup>
    <investigator>
      <last_name>John Bradley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Fearn</last_name>
      <email>LFearn@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>William Muller, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-2162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Malone</last_name>
      <phone>402-559-2977</phone>
      <email>Kristin.malone@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Kari Simonsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Robert Wood Johnson Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Cerrachio</last_name>
      <email>Lisa.Cerrachio@rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Sunanda Gaur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Childrens Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Toledo Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Vaborbactam</mesh_term>
    <mesh_term>beta-Lactamase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

